Clinical Trial Update: Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV Patients [Phase 2]

View source ↗

Summary

Phase 2 dose-ranging trial evaluating sofosbuvir in combination with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C patients; resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Pegylated interferon (pegylated interferon alfa)
• Ribavirin (ribavirin)
• Sovaldi (Sofosbuvir)

Snippet

Sponsor: Gilead Sciences | Conditions: Hepatitis C | Phase 2 | Status: COMPLETED | Results posted: 2014-02-19